Ikena Oncology, INC Form 4 insider transactions

Kristin Yarema, Chief Executive Officer and a Director of Ikena Oncology, Inc., reported multiple transactions in common stock on July 25, 2026.

Robert B Lally, Principal Accounting Officer of Ikena Oncology, Inc., sold 3,196 shares of common stock on July 16, 2026.

Jonathan Jian Wang, a Director at ImageneBio, Inc., acquired stock options for 15,600 shares.

ImageneBio, Inc. director Otello Stampacchia acquired stock options for 15,600 shares.

ImageneBio, Inc. reports that Director Joseph P. Slattery acquired stock options for 15,600 shares.

ImageneBio, Inc. Director David P. Bonita acquired 15,600 stock options with an exercise price of $5.45, vesting under specific conditions.

Director David P. Bonita reports the acquisition of pre-funded warrants by OrbiMed-affiliated entities in a private placement.

OrbiMed Advisors acquired 721,292 pre-funded warrants in a private placement transaction with ImageneBio, Inc.

ImageneBio CEO Kristin Yarema acquired 85,400 restricted stock units and 128,100 employee stock options on March 16, 2026, as part of her compensation.

ImageneBio's Principal Accounting Officer, Erin Butler, was granted 22,500 Restricted Stock Units and 22,500 employee stock options.

ImageneBio Director Joseph P. Slattery purchased 16,000 shares of common stock at $5.99 per share, signaling confidence.

ImageneBio, Inc. director Jonathan Jian Wang was granted 31,200 employee stock options with an exercise price of $6.19, vesting over three years.

ImageneBio, Inc. director Stephen Hui Wang was granted 31,200 employee stock options with an exercise price of $6.19, vesting over three years.

ImageneBio Director Joseph P. Slattery received an initial grant of 31,200 employee stock options with an exercise price of $6.19, vesting over three years.

ImageneBio Director Stephen Hui Wang reported the indirect acquisition of 250,721 common shares following the merger with Inmagene Biopharmaceuticals.

ImageneBio Director Jonathan Wang reported significant direct and indirect share acquisitions following the merger with Inmagene Biopharmaceuticals.

ImageneBio's Chief Medical Officer, Lu Yufang, received new employee stock options following the company's merger with Legacy Inmagene Biopharmaceuticals.

ImageneBio, Inc. CEO and Director Kristin Yarema was granted 460,515 employee stock options and 153,505 restricted stock units.

OrbiMed Advisors and its affiliates have reported an acquisition of common and non-voting common stock in ImageneBio, Inc., increasing their beneficial ownership.

ImageneBio, formerly Ikena Oncology, finalized its merger with Inmagene Biopharmaceuticals, accompanied by a 1:12 reverse stock split and a $75 million private placement.

ImageneBio, Inc. Director Otello Stampacchia reported the acquisition of shares by an affiliated entity and the cancellation of stock options, following the company's merger with Inmagene Biopharmaceuticals and a 1:12 reverse stock split.

ImageneBio, Inc.'s Chief Financial Officer, Jotin Marango, reported the acquisition of common stock and the disposition of shares for tax purposes following the merger between Ikena Oncology and Inmagene Biopharmaceuticals.

ImageneBio's Principal Accounting Officer, Erin Butler, acquired common stock and employee stock options as part of the equity conversion following the merger with Legacy Inmagene.

Ikena Oncology announced that leading independent proxy advisory firms, Institutional Shareholder Services (ISS) and Glass, Lewis & Co., recommend stockholders vote FOR the proposed merger with Inmagene Biopharmaceuticals.

Ikena Oncology's merger target, Inmagene Biopharmaceuticals, announced the successful dosing of the first patient in its global Phase 2b ADAPTIVE trial for IMG-007 in moderate-to-severe atopic dermatitis, with topline data expected in Q4 2026.

Inmagene Biopharmaceuticals announced positive topline results from a Phase 2a trial of IMG-007, showing significant reduction in eczema severity and a favorable safety profile for the treatment of atopic dermatitis.

Ikena Oncology and Inmagene Biopharmaceuticals have agreed to merge, with a $75 million private placement, to focus on developing IMG-007 for atopic dermatitis, creating a combined company with approximately $175 million in funding.

Jean-Francois Formela, a director at Ikena Oncology, acquired stock options for 17,520 shares at an exercise price of $1.75 on June 7, 2024.

Director David P. Bonita reports acquisition of stock options in Ikena Oncology, Inc.

Richard Wooster, a director of Ikena Oncology, acquired 17,520 stock options on June 7, 2024, at an exercise price of $1.75.